ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kinase inhibitor ATR in a synthetic lethal manner.
Saved in:
Main Authors: | Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/e641244f3cf24d9e87d1e6540b5b48bf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA
by: Demis Menolfi, et al.
Published: (2018) -
ATR harmony in Turkana
by: Manuela Noske
Published: (1996) -
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
by: Rebeka Sultana, et al.
Published: (2013) -
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
by: Ilirjana Bajrami, et al.
Published: (2021) -
ATR vowel harmony in Akposso
by: Coleen G. Anderson
Published: (1999)